Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ochsner Clinic Xigris Budget Projected At $2 Mil. Per Year

Executive Summary

The Ochsner Clinic Foundation estimates that its budget for Lilly's sepsis agent Xigris could be over $2 mil. per year.

You may also be interested in...



Xigris Inventory Strategy At Ochsner: 1.5 Doses Will Be Kept In Stock

The Ochsner Clinic Foundation is stocking enough vials of Lilly's Xigris to provide one and a half doses of the sepsis agent at any one time

Xigris Inventory Strategy At Ochsner: 1.5 Doses Will Be Kept In Stock

The Ochsner Clinic Foundation is stocking enough vials of Lilly's Xigris to provide one and a half doses of the sepsis agent at any one time

Xigris meeting rescheduled

FDA's Anti-Infective Drugs Advisory Committee will consider Lilly's Xigris (drotrecogin alfa) BLA on Oct. 16 at the Hilton in Gaithersburg, Md. starting at 8:30 a.m. The original Sept. 12 meeting was rescheduled following the terrorist attacks on Washington, D.C. and New York City (1"The Pink Sheet" Sept. 17, pp. 10 & 212)

Related Content

UsernamePublicRestriction

Register

PS038674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel